Maitland ML - Search Results

1

Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.

Bhatta SS, Wroblewski KE, Agarwal KL, Sit L, Cohen EE, Seiwert TY, Karrison T, Bakris GL, Ratain MJ, Vokes EE, Maitland ML. Bhatta SS, et al. Among authors: maitland ml. Oncologist. 2013;18(8):965-70. doi: 10.1634/theoncologist.2013-0006. Epub 2013 Jul 30. Oncologist. 2013. PMID: 23900000 Free PMC article.

2

Interpreting disparate responses to cancer therapy: the role of human population genetics.

Maitland ML, DiRienzo A, Ratain MJ. Maitland ML, et al. J Clin Oncol. 2006 May 10;24(14):2151-7. doi: 10.1200/JCO.2005.05.2282. J Clin Oncol. 2006. PMID: 16682733 Review.

3

TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?

Maitland ML, Vasisht K, Ratain MJ. Maitland ML, et al. Trends Pharmacol Sci. 2006 Aug;27(8):432-7. doi: 10.1016/j.tips.2006.06.007. Epub 2006 Jul 3. Trends Pharmacol Sci. 2006. PMID: 16815558 Review.

4

Terminal ballistics of kinase inhibitors: there are no magic bullets.

Maitland ML, Ratain MJ. Maitland ML, et al. Ann Intern Med. 2006 Nov 7;145(9):702-3. doi: 10.7326/0003-4819-145-9-200611070-00015. Ann Intern Med. 2006. PMID: 17088586 No abstract available.

5

Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.

Karrison TG, Maitland ML, Stadler WM, Ratain MJ. Karrison TG, et al. Among authors: maitland ml. J Natl Cancer Inst. 2007 Oct 3;99(19):1455-61. doi: 10.1093/jnci/djm158. Epub 2007 Sep 25. J Natl Cancer Inst. 2007. PMID: 17895472

6

Interpreting P values in pharmacogenetic studies: a call for process and perspective.

Maitland ML, Ratain MJ, Cox NJ. Maitland ML, et al. J Clin Oncol. 2007 Oct 10;25(29):4513-5. doi: 10.1200/JCO.2007.12.7803. J Clin Oncol. 2007. PMID: 17925544 No abstract available.

7

Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.

Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, Ratain MJ, Lussier YA, Garcia JG. Moreno-Vinasco L, et al. Among authors: maitland ml. Physiol Genomics. 2008 Apr 22;33(2):278-91. doi: 10.1152/physiolgenomics.00169.2007. Epub 2008 Feb 26. Physiol Genomics. 2008. PMID: 18303084 Free PMC article.

8

Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.

Snider KL, Maitland ML. Snider KL, et al. Among authors: maitland ml. Target Oncol. 2009 Apr;4(2):67-76. doi: 10.1007/s11523-009-0106-0. Epub 2009 Apr 17. Target Oncol. 2009. PMID: 19373440 Free PMC article. Review.

9

Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.

Maitland ML, Kasza KE, Karrison T, Moshier K, Sit L, Black HR, Undevia SD, Stadler WM, Elliott WJ, Ratain MJ. Maitland ML, et al. Clin Cancer Res. 2009 Oct 1;15(19):6250-7. doi: 10.1158/1078-0432.CCR-09-0058. Epub 2009 Sep 22. Clin Cancer Res. 2009. PMID: 19773379 Free PMC article.

10

Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.

Sharma MR, Maitland ML, Ratain MJ. Sharma MR, et al. Among authors: maitland ml. Cancer J. 2009 Sep-Oct;15(5):426-30. doi: 10.1097/PPO.0b013e3181b9c5d5. Cancer J. 2009. PMID: 19826363 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

87 results

Search Page